The cash-strapped Danish biotech has got some positive news flow on its vaccines for gonorrhea and melanoma and believes that Phase II data on the latter in particular will attract attention at the major oncology conference kicking off in Barcelona this week.

China’s NMPA import ban on a Dr Reddy’s ADHD drug due to manufacturing issues has left the firm calculating the monetary impact.

A licensing deal for Leqvio (inclisiran) is all in a day’s work for Mankind which also recently acquired Bharat Serums and Vaccines at a valuation investors were initially not entirely pleased with. As the youngest company in the top five of the domestic pharma market sets a 5X revenue target, what could help it get there and what’s to watch out for?

Does Zydus’ 50% stake acquisition in Sterling Biotech reflect a broader move of formulations companies to secure API supplies or acceleration of API segment restructuring begun by a couple of private equity (PE) funds?